Navigation Links
Tosedostat OPAL Study in Acute Myeloid Leukemia Published in Lancet Oncology
Date:3/4/2013

ww.celltherapeutics.com/">www.CellTherapeutics.com.

About Chroma Therapeutics

Chroma Therapeutics Limited, based in Oxford (UK), is a drug development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Phase4 and The Wellcome Trust. More information about Chroma can be found at www.chromatherapeutics.com.

References:

1. American Cancer Society, Cancer Facts & Figures 2012. Available at http://tinyurl.com/8kylgc7. Accessed February 2013.
2. The Leukemia and Lymphoma Society, Acute Myeloid Leukemia, Rev. 2011. Available at http://tinyurl.com/d72ycja. Accessed February 2013.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of tosedostat include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with tosedostat in particular including, without limitation, the potential failure of tosedostat to prove safe and effective for the treatment of AML, MDS, multiple myeloma, blood related cancers and solid tumors as determined by the U.S. Food and Drug Administration and/or the European Medicines Agency; that tosedostat may not be more effective when used in combination with azacytidine; that CTI cannot predict or guarantee the
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Longitudinal Study Highlights Evolving Role of Medical Science Liaisons with Thought Leaders and Product Development
2. New Study Shows Cannabis Effects on Driving Skills
3. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
4. University Hospitals Case Medical Center Presents Study On The Elimination Of Retained Surgical Sponges
5. MD+DI, the Global MedTech Authority, Publishes One-of-a-Kind Study with ITG Market Research on the Medical Device Outsourcing Landscape
6. New Direct-to-Consumer Prescription Delivery Channel Mitigates Risk of Medication Non-Adherence Highlighted in JAMA Internal Medicine Study
7. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
8. Study Shows Medicare Savings When Local Pharmacies Fill 90-Day Prescriptions
9. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
10. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
11. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 /CNW/ -   ... recalled after Health Canada tests confirmed it contains two ... (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution of ... product from retail stores across Canada ... including for weight loss and increased energy. ...
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping tips ... the models at LunaDress.co.uk come with big discounts, up to 80 ... can turn out to be a most exciting memory and can ... bring surprise to a wedding. On the updated fashion blog, ladies ... for a big day . , Going out with friends to ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... , LISLE, IL , Feb. 8 /PRNewswire-FirstCall/ - SXC ... a conference call on Thursday, March 4, 2010 at ... and year end financial results. Mark Thierer , President and CEO, ... the call. , All interested parties can join the call by dialing ...
... A team of researchers, led by Pier Paolo Pandolfi, ... a new type of cellular senescence (i.e., irreversible arrest ... it to suppress prostate tumor development and growth in ... that inactivation of the protein Pten leads to a ...
... with Alzheimer,s disease (latrepirdine) appears well tolerated and may ... Huntington,s disease, according to a report in the February ... the JAMA/Archives journals. "Huntington,s disease is a hereditary ... leads to death within 20 years of disease onset," ...
... trouble organizing thoughts, but not memory loss , MONDAY, ... predict dementia in older adults with impaired executive function ... those with memory problems, a new study has found. ... 83, who were followed-up for five years. During that ...
... ... industry professionals, academics, and students to discuss the key issues facing the health care ... groundbreaking ways in which companies and individuals across every sector of health care are ... ...
... , PHILADELPHIA , Feb. 8 Independence Blue ... to the newly created role of senior vice president of ... and chief marketing executive, Linda M. Taylor . , ... that help health care consumers better manage their care and will ...
Cached Medicine News:Health News:SXC Health Solutions to Host Fiscal 2009 Fourth Quarter and Year End Results Conference Call 2Health News:Medication appears well-tolerated, beneficial in Huntington's disease patients 2Health News:High Blood Pressure May Predict Dementia in Some Seniors 2Health News:2010 Wharton Health Care Business Conference - Feb. 25-26, Philadelphia, PA 2Health News:2010 Wharton Health Care Business Conference - Feb. 25-26, Philadelphia, PA 3Health News:Independence Blue Cross Names John Janney to Newly Created Position: Senior Vice President Marketing Services 2Health News:Independence Blue Cross Names John Janney to Newly Created Position: Senior Vice President Marketing Services 3
Revised Drug calibrator that replaces existing Drug calibrator - this product contains Lithium in addition to Digoxin, Phenobarbital, OPhenytoin, & Theophulline....
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....
... The BD Macro-Vue RPR (Rapid Plasma ... Tear-drop Tests are nontreponemal testing procedures ... described in A Manual of Tests ... this manual are the most widely ...
Medicine Products: